These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991 [TBL] [Abstract][Full Text] [Related]
6. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype. Giembycz MA; Newton R Clin Chest Med; 2014 Mar; 35(1):203-17. PubMed ID: 24507847 [TBL] [Abstract][Full Text] [Related]
7. [Phosphodiesterase-4 inhibitors: a new target in treatment of COPD]. Michels G; Erdmann E; Pfister R Dtsch Med Wochenschr; 2011 Nov; 136(44):2267-70. PubMed ID: 22028292 [TBL] [Abstract][Full Text] [Related]
8. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586 [TBL] [Abstract][Full Text] [Related]
9. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384 [TBL] [Abstract][Full Text] [Related]
10. Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting. Pleasants RA; Radlowski PA; Davidson HE Drugs Aging; 2019 Aug; 36(8):733-745. PubMed ID: 31172422 [TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847 [TBL] [Abstract][Full Text] [Related]
14. Roflumilast for the treatment of chronic obstructive pulmonary disease. Antoniu SA Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716 [TBL] [Abstract][Full Text] [Related]
15. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD]. Martínez FJ Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811 [No Abstract] [Full Text] [Related]
16. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. Cazzola M; Picciolo S; Matera MG Expert Opin Pharmacother; 2010 Feb; 11(3):441-9. PubMed ID: 20102307 [TBL] [Abstract][Full Text] [Related]
18. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416 [TBL] [Abstract][Full Text] [Related]
19. New therapy for managing moderate to severe chronic obstructive pulmonary disease. Chou A; D'Urzo AD Can Fam Physician; 2014 Apr; 60(4):352-4. PubMed ID: 24733327 [No Abstract] [Full Text] [Related]
20. Alternatives to indicating roflumilast and the chronic obstructive pulmonary disease classification. Blasco LM Arch Bronconeumol; 2012 Sep; 48(9):343. PubMed ID: 22503591 [No Abstract] [Full Text] [Related] [Next] [New Search]